The stock has climbed 6.2% year-to-date. For the 2025/2026 ski season, Epic Pass sales revenue grew by 3% despite a decline ...

Teleflex announced a major leadership transition effective January 7–8, 2026, with long-time Chairman, President and CEO Liam Kelly departing and board member Stuart Randle, a veteran medical device ...

Defense stocks surged Thursday, erasing the prior session's losses, after President Donald Trump floated a sharp increase in ...

Stock futures exhibited mixed performance on Thursday, as market participants braced for key U.S. employment data later in ...

Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Reve ...

Teleflex announced today that Chair, President and CEO Liam Kelly is departing the company, effective immediately.

Discover the top 3 undervalued Health Care Equipment & Supplies stocks for Monday, January 05 based on AAII’s Stock Grades.

Medtronic disclosed Diabetes unit executive pay packages for 2025 and compensation targets for when they'll lead MiniMed as a ...

US stock markets finished the year in disappointing fashion, falling for the fourth straight session as investors continued to book profits following recent record highs from the Dow and S&P 500.

In a report released on December 16, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Insulet, with a price target of $380.00. The company’s shares closed yesterday at $288.73.

Teleflex’s TFX Interventional Urology portfolio is well positioned for sustained growth, led by UroLift’s expanding global footprint and strong clinical differentiation. Supported by favorable ...